GlassScriptPhysician profile
William Eschenbacher
NPI 1659733947
$7,597.37
in general payments reported to CMS, 2019-2025
27 companies · $2,232 in 2025
The $2,232 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2021: $166 · 2022: $1,067 · 2023: $1,425 · 2024: $1,980 · 2025: $2,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,624 · Education: $12.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,623.93 |
| Education | $12.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,505.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,045.43 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $816.90 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $809.49 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $672.69 | 2021-2025 | Haegarda, Andembry, Hizentra |
| Novartis Pharmaceuticals Corporation | $626.68 | 2022-2025 | |
| Amgen INC. | $285.61 | 2022-2025 | Tezspire, Actimmune |
| Grifols USA, LLC | $263.05 | 2023-2025 | Xembify |
| Genentech USA, INC. | $238.46 | 2019-2025 | Xolair |
| Kaleo, INC. | $183.04 | 2021-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $163.81 | 2022-2025 | Takhzyro, Cuvitru, Eohilia |
| Blueprint Medicines Corporation | $155.26 | 2023-2025 | Ayvakit |
| Pfizer INC. | $137.95 | 2022-2024 | |
| Ars Pharmaceuticals Operations, INC. | $90.33 | 2025 | Neffy |
| Lilly USA, LLC | $89.50 | 2025 | Ebglyss |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $82.88 | 2025 | Dawnzera |
| Octapharma USA, INC. | $73.36 | 2023-2025 | Cutaquig |
| Leo Pharma INC. | $60.75 | 2022-2023 | Adbry |
| Aimmune Therapeutics, INC. | $53.42 | 2022 | |
| Cycle Pharmaceuticals INC | $44.37 | 2025 | Sajazir |
| Pharming Healthcare, INC. | $36.29 | 2023-2025 | Ruconest |
| Galderma Laboratories, L.P. | $35.68 | 2025 | Nemluvio |
| Horizon Therapeutics Plc | $30.95 | 2022-2023 | Actimmune |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.24 | 2022 | |
| Incyte Corporation | $27.09 | 2022 | |
| Abbvie INC. | $26.54 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.66 | 2023 | Airduo Digihaler |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Eschenbacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.